MedTrace Logo

Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis

NCT05986162 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2023-08-14

No results posted yet for this study

Summary

To evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of Itolizumab in subjects with Dermatomyositis.

Conditions

  • Dermatomyositis, Adult Type

Interventions

DRUG

Itolizumab

Patients to be treated with Itolizumab.

Sponsors & Collaborators

  • Biotech Pharmaceutical Co., Ltd.

    lead OTHER

Principal Investigators

  • Xiaofeng Zeng · Peking Union Medical College Hospital

  • Rui Chen · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-30
Primary Completion
2025-05-03
Completion
2025-06-25

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05986162 on ClinicalTrials.gov